Understanding Your Options for Ozempic and Personalized Weight Loss

Last reviewed: June 27, 2026

Last updated: June 27, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The first thing to understand about your options for Ozempic and weight loss is that Ozempic is not a weight-loss medication. The Ozempic prescribing information lists three indications, and all three are type 2 diabetes indications: improving glycemic control as an adjunct to diet and exercise, reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. There is no weight-management indication anywhere in that label. If weight is what you are trying to address, the honest version of "your options" is a different and larger list than most people arrive expecting — and it includes both injections and, as of the last several months, tablets.

What Ozempic Is and Is Not Approved to Do

Ozempic contains semaglutide, which the label describes as "a GLP-1 analogue with 94% sequence homology to human GLP-1" that "acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1." That mechanism affects appetite and gastric emptying as well as insulin secretion, which is why weight change shows up as a secondary outcome throughout the diabetes trial program.

An indication is not a summary of everything a molecule does. It is a regulatory statement about the population and purpose for which a sponsor submitted evidence and the FDA agreed the benefit-risk balance was favorable. Semaglutide's weight-management evidence was generated in a separate trial program, submitted under a separate application, and approved under a separate brand. Understanding that distinction is what turns a confused search into a productive conversation with a prescriber.

Ozempic Is Now Available as a Tablet

A common assumption — that Ozempic exists only as an injection — is out of date. The current FDA label covering oral semaglutide, revised in January 2026, is titled for RYBELSUS and OZEMPIC tablets. Rybelsus is available in 3 mg, 7 mg, and 14 mg strengths; Ozempic tablets are available in 1.5 mg, 4 mg, and 9 mg.

Both are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events. So the tablet form does not change the indication picture — it changes the route of administration. An oral option is still a type 2 diabetes option.

For Weight Management, Wegovy Is the Semaglutide Brand

The same active ingredient carries a weight-management approval under the brand name Wegovy. According to the Wegovy prescribing information, Wegovy injection is indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; for weight reduction in adults and in pediatric patients aged 12 years and older with obesity, and in adults with overweight plus at least one weight-related condition; and for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis in adults.

Wegovy tablets now sit inside that same label, in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths. Notably, the tablets carry a narrower set of indications than the injection — cardiovascular risk reduction and weight reduction in adults only, without the pediatric or liver-disease indications. Two products, one molecule, and materially different labeled uses. That is exactly the kind of detail that gets flattened in casual conversation and matters enormously when you are deciding what to ask for.

The Tirzepatide Option Is a Different Molecule Entirely

Tirzepatide is not semaglutide. It is a dual agonist that acts at both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor, and it is marketed as two separate products with two separate approvals. Mounjaro is approved for glycemic control in type 2 diabetes. Zepbound is indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight plus at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.

The head-to-head evidence base is thinner than the marketing suggests, and mechanism alone does not predict who does well on what. What is clear is that these are four distinct approved products across two molecules, and the right question for a prescriber is not "which one is strongest" but "which labeled indication actually matches my diagnosis."

Where Compounded Semaglutide Fits

Compounded semaglutide is a separate regulatory category from all of the above. It is not an FDA-approved finished product, and the FDA does not review compounded preparations for safety, effectiveness, or quality before they are marketed. It is prepared by a licensed pharmacy pursuant to a prescription written for an individual patient, which is what distinguishes a legitimate compounded preparation from material sold directly to consumers as a research chemical.

It is also not a generic. Wegovy and Ozempic are the FDA-approved semaglutide brands, and no approved generic version of either exists. Describing a compounded preparation as a generic misstates both its regulatory status and the evidence behind it. Anyone offering you semaglutide should be able to state plainly which category their product falls into and which licensed pharmacy dispenses it.

What "Personalized" Should Actually Mean

Personalization in this category is often marketing language for a questionnaire. The version worth paying for is narrower and more honest: a real clinical intake that captures your diagnoses, your other medications, your history with prior therapies, and your tolerance for side effects, reviewed by a licensed prescriber who is willing to say no.

Response to GLP-1 therapy varies widely between individuals, and no intake form, lab panel, or genetic report can tell you in advance how much weight you will lose. What a good process can do is narrow the field, surface contraindications early, and give you and your provider a shared basis for a decision — rather than defaulting to whichever brand name you happened to search for first.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic approved for weight loss?

No. The Ozempic prescribing information lists three indications, all of them in type 2 diabetes: improving glycemic control, reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with chronic kidney disease. There is no weight-management indication in that label.

Is there an Ozempic pill?

Yes. The current FDA label revised in January 2026 covers both Rybelsus and Ozempic tablets. Rybelsus comes in 3 mg, 7 mg, and 14 mg; Ozempic tablets come in 1.5 mg, 4 mg, and 9 mg. Both are indicated for glycemic control in adults with type 2 diabetes and for reducing major adverse cardiovascular event risk in adults with type 2 diabetes at high risk. Neither carries a weight-management indication.

What is the difference between Ozempic and Wegovy?

Both contain semaglutide, but they are separate products with separate FDA applications and labeling. Ozempic is approved only for type 2 diabetes indications. Wegovy is approved for weight reduction, cardiovascular risk reduction in adults with obesity or overweight and established cardiovascular disease, and noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. Wegovy also now exists in tablet form.

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Compounded semaglutide is not an FDA-approved finished product, and the agency does not review compounded preparations for safety, effectiveness, or quality before marketing. It is prepared by a licensed pharmacy pursuant to a prescription for an individual patient. It is not a generic version of any approved brand, because no approved generic semaglutide exists in the United States.

How do I decide which option is right for me?

That decision belongs to a licensed prescriber who can review your diagnoses, current medications, medical history, and prior treatment experience. The most useful preparation you can do is to know which labeled indication matches your situation, since coverage, prescribing, and the underlying evidence base all follow the indication rather than the molecule. Bring that question to your appointment.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.